Tvardi Therapeutics Q1 EPS $(3.22) Misses $(0.31) Estimate, Sales $2.57M Up From $2.13M YoY

Tvardi Therapeutics (NASDAQ: TVRD) reported quarterly losses of $(3.22) per share which missed the analyst consensus estimate of $(0.31) by 938.71 percent. This is a 84.09 percent increase over losses of $(20.24) per share from the same period last year. The company reported $2.57 million in sales this quarter. This is a 20.33 percent increase over sales of $2.13 million the same period last year.